DAPA-CKD
2020
Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease
In 4,304 patients with CKD with or without diabetes, dapagliflozin reduced the composite of ≥50% eGFR decline, ESKD or renal/CV death compared with placebo.
Result
Efficacy: ≥50% eGFR decline, ESKD, or renal or CV deathHR 0.61 (95% CI 0.51-0.72) · P < 0.001
Below 1 favours dapagliflozin, above 1 favours placebo.
- Absolute difference
- 5.3 points
- NNT
- 19
Absolute difference and NNT are derived from the event rates.
Also reported: All-cause mortality HR 0.69.
- Subtopic
- SGLT2 inhibitors
- Design
- Double-blind RCT, stopped early
- Relevance
- Practice-defining: a trial the guidelines cite as evidence.
- Cited in
- ESC 2026 CVD & CKDESC 2023 DiabetesACC/AHA 2026 CKMKDIGO 2024 CKDKDIGO 2022 Diabetes in CKDKDIGO 2025 IgA Nephropathy
- Also listed in
- Diabetes & cardiometabolic
- Source
- Heerspink HJL, et al. N Engl J Med. 2020;383(15):1436-1446.doi 10.1056/NEJMoa2024816
Discussion & critique
Extended SGLT2-inhibitor benefit to non-diabetic CKD; dialysis patients were excluded.